Delivery of immunogens to mucosal immune system using an oral inactivated cholera vaccine: A new approach for development of oral vaccines

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 7, 2013, Pages 1445-1448

  Azizi, Ali ^a   Ghunaim, Haitham ^b   Sirskyj, Danylo ^a,b   Fallahi, Firouzeh ^c   Le, Hoang Thanh ^d   Kumar, Ashok ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c CANADIAN FOOD INSPECTION AGENCY   (Canada)

^d SUDBURY REGIONAL HOSPITAL   (Canada)

Author keywords

Immune response; Immunogens; M cells; Mucosal; Oral vaccines

Indexed keywords

ANTIGEN; CELL PROTEIN; CHOLERA VACCINE; DENDRIMER; GLYCOPROTEIN 2; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; ISCOM; LIPOSOME; MYELOID DIFFERENTIATION FACTOR 88; POLYGLACTIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG;

BETA CHAIN; BONE MARROW DERIVED IMMATURE DENDRITIC CELL; CELLULAR IMMUNITY; CHOLERA; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENZYME DEGRADATION; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; MUCOSAL IMMUNITY; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PARTICLE SIZE; VIBRIO CHOLERAE;

IMMUNE RESPONSE; IMMUNOGENS; M CELLS; MUCOSAL; ORAL VACCINES;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADMINISTRATION, ORAL; ANIMALS; ANTIBODY FORMATION; CHOLERA VACCINES; IMMUNOGLOBULIN G; MICE; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; PHARMACEUTICAL VEHICLES; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; VACCINATION; VACCINES, INACTIVATED; VIBRIO CHOLERAE;

EID: 84880861978     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24200     Document Type: Note

References (23)

1. McGhee Jr. A mucosal gateway for vaccines. Nat Biotechnol 2011; 29:136-8; PMID:21301439; http://dx.doi.org/10.1038/nbt.1766.
2. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992; 10:75-88; PMID:1539467; http://dx.doi.org/10.1016/0264-410X(92) 90021-B.
3. McGhee JR, Kiyono H. Mucosal immunity to vaccines: current concepts for vaccine development and immune response analysis. Adv Exp Med Biol 1992; 327:3-12; PMID:1295349; http://dx.doi. org/10.1007/978-1-4615-3410-5-2.
4. Azizi A, Ghunaim H, Diaz-Mitoma F, Mestecky J. Mucosal HIV vaccines: a holy grail or a dud? Vaccine 2010; 28:4015-26; PMID:20412879; http://dx.doi. org/10.1016/j.vaccine.2010.04.018.
5. Azizi A, Kumar A, Diaz-Mitoma F, Mestecky J. Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog 2010; 6:e1001147; PMID:21085599; http://dx.doi.org/10.1371/journal. ppat.1001147.
6. Parr EL, Parr MB. A comparison of antibody titres in mouse uterine fluid after immunization by several routes, and the effect of the uterus on antibody titres in vaginal fluid. J Reprod Fertil 1990; 89:619-25; PMID:2401988; http://dx.doi.org/10.1530/jrf.0.0890619.
7. Katz DE, DeLorimier AJ, Wolf MK, Hall ER, Cassels FJ, van Hamont JE, et al. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 2003; 21:341-6; PMID:12531630; http://dx.doi.org/10.1016/S0264-410X(02)00613-8.
8. Frey A, Giannasca KT, Weltzin R, Giannasca PJ, Reggio H, Lencer WI, et al. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med 1996; 184:1045-59; PMID:9064322; http://dx.doi.org/10.1084/jem.184.3.1045.
9. Italia JL, Kumar MN, Carter KC. Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis. J Biomed Nanotechnol 2012; 8:695-702; PMID:22852479; http://dx.doi.org/10.1166/jbn.2012.1414.
10. Mann JF, Scales HE, Shakir E, Alexander J, Carter KC, Mullen AB, et al. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods 2006; 38:90-5; PMID:16414269; http://dx.doi.org/10.1016/j.ymeth.2005.11.002.
11. Shukla A, Katare OP, Singh B, Vyas SP. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm 2010; 385:47-52; PMID:19835938; http://dx.doi.org/10. 1016/j.ijpharm.2009.10.027.
12. Shukla A, Khatri K, Gupta PN, Goyal AK, Mehta A, Vyas SP. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharm Sci 2008; 11:59-66; PMID:18445364.
13. Rescia VC, Takata CS, de Araujo PS, Bueno da Costa MH. Dressing liposomal particles with chitosan and poly(vinylic alcohol) for oral vaccine delivery. J Liposome Res 2011; 21:38-45; PMID:20470223; http://dx.doi.org/10.3109/ 08982101003735988.
14. van der Lubben IM, Verhoef JC, van Aelst AC, Borchard G, Junginger HE. Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials 2001; 22:687-94; PMID:11246962; http://dx.doi.org/10.1016/S0142-9612(00)00231-3.
15. Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, et al. A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine 2001; 19:3033-42; PMID:11311997; http://dx.doi.org/10.1016/S0264-410X(01)00051-2.
16. Wright PF, Mestecky J, McElrath MJ, Keefer MC, Gorse GJ, Goepfert PA, et al.; National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis 2004; 189:1221-31; PMID:15031791; http://dx.doi.org/10. 1086/382088.
17. Azizi A, Anderson DE, Torres JV, Ogrel A, Ghorbani M, Soare C, et al. Induction of broad cross-subtypespecific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques. J Immunol 2008; 180:2174-86; PMID:18250424.
18. Ghunaim H, Kumar A, Torres J, Diaz-Mitoma F, Azizi A. An immunological comparison between lipidated and non-lipidated multivalent HIV-1 peptides representing Gp120 and Gag hypervariable regions. Vaccine 2011; 29:5950-8; PMID:21718739; http://dx.doi.org/10.1016/j.vaccine.2011.06.047.
19. Jelinek T, Kollaritsch H. Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera. Expert Rev Vaccines 2008; 7:561-7; PMID:18564011; http://dx.doi.org/10.1586/14760584.7.5.561.
20. Bunyakul N, Edwards KA, Promptmas C, Baeumner AJ. Cholera toxin subunit B detection in microfluidic devices. Anal Bioanal Chem 2009; 393:177-86; PMID:18777170; http://dx.doi.org/10.1007/s00216-008-2364-6.
21. Hase K, Kawano K, Nochi T, Pontes GS, Fukuda S, Ebisawa M, et al. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 2009; 462:226-30; PMID:19907495; http://dx.doi.org/10.1038/ nature08529.
22. Bauer S, Müller T, Hamm S. Pattern recognition by Toll-like receptors. Adv Exp Med Biol 2009; 653:15-34; PMID:19799109; http://dx.doi.org/ 10.1007/978-1-4419-0901-5-2.
23. Kirschning CJ, Bauer S. Toll-like receptors: cellular signal transducers for exogenous molecular patterns causing immune responses. Int J Med Microbiol 2001; 291:251-60; PMID:11680785; http://dx.doi.org/10.1078/1438-4221-00128.